Immunovant, Inc. (IMVT)
NASDAQ: IMVT · IEX Real-Time Price · USD
27.17
-0.58 (-2.09%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Immunovant Employees
Immunovant had 164 employees on March 31, 2023. The number of employees increased by 40 or 32.26% compared to the previous year.
Employees
164
Change (1Y)
40
Growth (1Y)
32.26%
Revenue / Employee
n/a
Profits / Employee
-$1,484,445
Market Cap
3.95B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2023 | 164 | 40 | 32.26% |
Mar 31, 2022 | 124 | 56 | 82.35% |
Mar 31, 2021 | 68 | 26 | 61.90% |
Mar 31, 2020 | 42 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Integer Holdings | 10,500 |
Perrigo Company | 9,140 |
Merit Medical Systems | 6,950 |
Alkermes | 2,100 |
Ultragenyx Pharmaceutical | 1,276 |
Alvotech | 1,026 |
Insmed | 912 |
Madrigal Pharmaceuticals | 376 |
IMVT News
- 6 weeks ago - Immunovant Awarded U.S. Patent for IMVT-1402 - GlobeNewsWire
- 2 months ago - Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023 - GlobeNewsWire
- 4 months ago - Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease - GlobeNewsWire
- 4 months ago - Best Small-Cap Stocks to Buy for 2024 and Beyond - Kiplinger
- 5 months ago - Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential - GlobeNewsWire
- 5 months ago - Immunovant to Present at Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023 - GlobeNewsWire